ArticleAmerican journal of cancer research2025
A novel tumor-associated macrophage risk signature predicts prognosis and immunotherapy response in lung adenocarcinoma.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo systematically characterize tumor-associated macrophage (TAM) subsets in lung adenocarcinoma (LUAD) and establish a TAM-based prognostic risk signature for LUAD patients.
methodsSingle-cell RNA sequencing (scRNA-seq) and bulk transcriptomic data were integrated to identify TAM subsets linked to LUAD prognosis. Prognostic genes were screened using univariate Cox regression, refined via Least Absolute Shrinkage and Selection Operator (LASSO) regression, and used to construct a 10-gene risk signature. The signature's performance was validated in independent cohorts through receiver operating characteristic curves, Kaplan-Meier survival analysis, and a nomogram. Its predictive ability for immune checkpoint inhibitor (ICI) therapy response was assessed in the IMvigor210 and GSE78220 datasets.
resultsSix distinct TAM subpopulations were identified, with two subsets significantly correlated with poor prognosis. The 10-gene risk signature, derived from TAM-related genes, demonstrated strong prognostic performance in both training and validation cohorts. High-risk patients exhibited markedly worse overall survival compared to low-risk patients. Additionally, the signature effectively stratified patients based on their response to anti-PD-L1 therapy, with high-risk patients exhibiting reduced clinical benefit. A nomogram combining the risk signature with clinicopathological parameters further enhanced survival prediction accuracy, supporting its clinical applicability.
conclusionThis study established a novel TAM-based prognostic risk signature with robust predictive power for both survival outcomes and immunotherapy response in LUAD. These findings enhance our understanding of TAMs' clinical significance and provide a foundation for personalized immunotherapy strategies in LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.